Blog Posts by Tag: Automation
Overcoming Reimbursement Compression: The Latest Trends in Denials for Laboratories and Pathology Practices
This is the second article in a three-part series on denial and appeals trends. This article focuses on claim denial trends by payor group and by market segment, and denial trends for claims with a 2021 date of service differ from a similar analysis completed on claims with dates of service in 2018. If you missed the first article in this series on the importance of physician engagement in...
Denials and Appeals Management: The Importance of Patient Engagement
Revenue cycle management (RCM) for laboratories and pathology practices is constantly evolving in complexity. Payors introduce new and more rigid policies that make collecting reimbursement for services rendered increasingly difficult. XiFin recently published a new whitepaper, Overcoming Reimbursement Compression: The Latest Trends in Denials and Appeals Management for Laboratories and...
Automation Strategies for Molecular Diagnostic Market-Share Expansion
This blog post is the third in our series covering the keys to success for market-share expansion in molecular diagnostics based on our recently published whitepaper, “The Executive’s Guide to Molecular Diagnostic Market-Share Expansion”. If you missed either of the first two posts in this series, you can find the first post, “Molecular Diagnostic Market-Share Expansion: Keys to Success” here and...
The Importance of Physician and Patient Engagement for Molecular Diagnostic Market-Share Expansion
This blog is the second in our series covering the keys to success for market-share expansion in molecular diagnostics outlined in our recent whitepaper, “The Executive’s Guide to Molecular Diagnostic Market-Share Expansion”. We encourage you to read Part 1 and Part 3.As more molecular diagnostic testing moves from physician offices and laboratories to the home, molecular diagnostics...
Molecular Diagnostic Market-Share Expansion: Keys to Success
This blog is part of a series. We encourage you to read Part 2 here and Part 3. The molecular diagnostics market has experienced tremendous growth in recent years. It’s a complex business with many challenges, including prior authorization requirements, diagnostic coding changes, the evolving regulatory landscape, and specimen collection moving from physician offices and laboratories to the home...